Abstract: The formation reason of malignant ascites（MA）in patients with advanced cancer is a key issue in clinical oncology，which may cause the most serious manifestations，including severe abdominal pain，cachexia，anorexia，fatigue，etc. Many researchers have recently found high vascular endothelial growth factor （VEGF） expression in isolated malignant effusions. Although it can′t be determined whether VEGF is the cause of malignant effusions， its antagonist endostatin （recombinant human endostatin） has a promising development prospect in treating malignant ascites. The hyperthermic perfusion chemotherapy technology emerging in recent years is adjuvant therapy for rare intraabdominal diseases. The chemotherapeutic drugs and hyperthermic perfusion therapy have a synergistic effect，and the thermal effect helps the drugs enter the tumor cells and exert a good killing effect. This paper introduces the research results and clinical experience of Endostat combined with hyperthermic perfusion in treating malignant ascites，and reviews the research of Endostat combined with hyperthermic perfusion in treating malignant ascites based on recent domestic and foreign papers.

Key words: recombinant human endostatin/endostatin, hyperthermic perfusion, tumor, malignant ascites